Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REACH: Hydroxyurea for Children With Sickle Cell Anemia
NCT06171217Phase 2Active, not recruiting
- Sponsor
- Cincinnati Children's Hospital Medical Center
- Start
- Oct 2023
- Primary completion
- Oct 2027
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, open-label trial of hydroxyurea in sickle cell anemia (SCA) (2 cohorts), sponsored by Cincinnati Children's Hospital Medical Center. Primary endpoint: Efficacy of long-term Hydroxyurea treatment at MTD up to 204 months. Started Oct 2023; status: active, not recruiting.
02
Drugs
hydroxyurea
03
Conditions
sickle cell anemia (SCA)
Beyond the preview
Go deeper on NCT06171217.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06171217.